Rapid Antifungal Susceptibility Testing by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Analysis

ABSTRACT The widespread use of antifungal agents, which is likely to expand with their enhanced availability, has promoted the emergence of drug-resistant strains. Antifungal susceptibility testing (AFST) is now an essential procedure for guiding appropriate antifungal therapy. Recently, we developed a matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS)-based method that enables the detection of fungal isolates with reduced echinocandin susceptibility, relying on the proteome changes that are detectable after a 15-h exposure of fungal cells to serial drug concentrations. Here, we describe a simplified version of this approach that facilitates discrimination of the susceptible and resistant isolates of Candida albicans after a 3-h incubation in the presence of “breakpoint” level drug concentrations of the echinocandin caspofungin (CSF). Spectra at concentrations of 0 (null), 0.03 (intermediate), and 32 (maximal) μg/ml of CSF were used to create individual composite correlation index (CCI) matrices for 65 C. albicans isolates, including 13 fks1 mutants. Isolates are then classified as susceptible or resistant to CSF if the CCI values of spectra at 0.03 and 32 μg/ml are higher or lower, respectively, than the CCI values of spectra at 0.03 and 0 μg/ml. In this way, the drug resistance of C. albicans isolates to echinocandin antifungals can be quickly assessed. Furthermore, the isolate categorizations determined using MALDI-TOF MS-based AFST (ms-AFST) were consistent with the wild-type and mutant FKS1 genotypes and the AFST reference methodology. The ms-AFST approach may provide a rapid and reliable means of detecting emerging antifungal resistance and accelerating the initiation of appropriate antifungal treatment.

[1]  A. Bizzini,et al.  Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  SC Chen,et al.  Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison , 2012, Drugs.

[3]  B. Posteraro,et al.  Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Caspofungin Susceptibility Testing of Candida and Aspergillus Species , 2012, Journal of Clinical Microbiology.

[4]  T. Calandra,et al.  Invasive candidiasis in critically ill patients: does progressing knowledge improve clinical management and outcome? , 2010, Current opinion in critical care.

[5]  M. Bassetti,et al.  Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. , 2007, Diagnostic microbiology and infectious disease.

[6]  M. Arendrup,et al.  Evaluation of Caspofungin Susceptibility Testing by the New Vitek 2 AST-YS06 Yeast Card Using a Unique Collection of FKS Wild-Type and Hot Spot Mutant Isolates, Including the Five Most Common Candida Species , 2012, Antimicrobial Agents and Chemotherapy.

[7]  M. Falagas,et al.  Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  D. Perlin Current perspectives on echinocandin class drugs. , 2011, Future microbiology.

[9]  I. Wybo,et al.  Differentiation of cfiA-Negative and cfiA-Positive Bacteroides fragilis Isolates by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry , 2011, Journal of Clinical Microbiology.

[10]  D. Raveh,et al.  Direct fluconazole susceptibility testing of positive Candida blood cultures by flow cytometry , 2008, Mycoses.

[11]  A. Bal The echinocandins: three useful choices or three too many? , 2010, International journal of antimicrobial agents.

[12]  Steven D. Brown,et al.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[13]  J. Torre-Cisneros,et al.  Epidemiology of invasive fungal infection. , 2008, International journal of antimicrobial agents.

[14]  F. Tsai,et al.  Peptide biomarker discovery for identification of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus strains by MALDI-TOF. , 2012, Analytical chemistry.

[15]  M. Arendrup Epidemiology of invasive candidiasis , 2010, Current opinion in critical care.

[16]  V. Havlíček,et al.  Current trends in microbial diagnostics based on mass spectrometry. , 2013, Analytical chemistry.

[17]  D. Perlin Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  J P Reilly,et al.  Fingerprint matching of E. coli strains with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of whole cells using a modified correlation approach. , 1998, Rapid communications in mass spectrometry : RCM.

[19]  M. Pfaller,et al.  Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.

[20]  Steven D. Brown,et al.  Evaluation of CLSI M44-A2 Disk Diffusion and Associated Breakpoint Testing of Caspofungin and Micafungin Using a Well-Characterized Panel of Wild-Type and fks Hot Spot Mutant Candida Isolates , 2011, Antimicrobial Agents and Chemotherapy.

[21]  C. Lass‐Flörl,et al.  In vitro susceptibility testing in fungi: a global perspective on a variety of methods , 2010, Mycoses.

[22]  M. Arendrup,et al.  Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species , 2009, Antimicrobial Agents and Chemotherapy.

[23]  John R Perfect,et al.  Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .

[24]  D. Perlin,et al.  Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.

[25]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[26]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[27]  M. Ghannoum,et al.  Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. , 2012, Diagnostic microbiology and infectious disease.

[28]  Maurizio Sanguinetti,et al.  Direct MALDI-TOF Mass Spectrometry Assay of Blood Culture Broths for Rapid Identification of Candida Species Causing Bloodstream Infections: an Observational Study in Two Large Microbiology Laboratories , 2011, Journal of Clinical Microbiology.

[29]  C. Munro,et al.  Fungal echinocandin resistance , 2010, F1000 biology reports.

[30]  B. Posteraro,et al.  Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry-Based Method for Discrimination between Molecular Types of Cryptococcus neoformans and Cryptococcus gattii , 2012, Journal of Clinical Microbiology.

[31]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[32]  M. Cuenca‐Estrella,et al.  EUCAST and CLSI: How to Assess in Vitro Susceptibility and Clinical Resistance , 2012, Current Fungal Infection Reports.

[33]  E. Chahine,et al.  Echinocandins: The Newest Class of Antifungals , 2009, The Annals of pharmacotherapy.

[34]  S. Sauer,et al.  Phylogenetic classification and identification of bacteria by mass spectrometry , 2009, Nature Protocols.

[35]  G. Fadda,et al.  Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[36]  George M. Hilliard,et al.  Changes in the Proteome of Candida albicans in Response to Azole, Polyene, and Echinocandin Antifungal Agents , 2010, Antimicrobial Agents and Chemotherapy.

[37]  A. Groll,et al.  Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009 , 2011, Mycoses.

[38]  Christophe Hennequin,et al.  MALDI‐TOF MS‐based drug susceptibility testing of pathogens: The example of Candida albicans and fluconazole , 2009, Proteomics.

[39]  Jong-Hee Shin Current Status of Antifungal Susceptibility Testing: Methods and Clinical Application , 2009 .

[40]  F. Marty,et al.  Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? , 2010, The Journal of antimicrobial chemotherapy.

[41]  J. Meis,et al.  Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide , 2012, PloS one.

[42]  S. Arikan Current status of antifungal susceptibility testing methods. , 2007, Medical mycology.

[43]  P. Murray,et al.  Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: usefulness for taxonomy and epidemiology. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  D. Denning,et al.  New and emerging treatments for fungal infections. , 2008, The Journal of antimicrobial chemotherapy.